8.3 C
New York
HomeTop Global NewsAstraZeneca adds to obesity drug race, but Eli Lilly remains in lead

AstraZeneca adds to obesity drug race, but Eli Lilly remains in lead


David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN).



Source link

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here